Kent Expands Free Lung Screening for Smokers and Ex-Smokers
Smokers and ex-smokers in parts of Kent are being brought into a free lung cancer screening programme designed to find disease before symptoms take hold. Maidstone and Tunbridge Wells NHS Trust is inviting people aged 55 to 74 to attend checks at the Royal Victoria Shopping Centre, while West Kent patients are now being screened at the Fordcombe site.
Early detection is the point. Lung cancer often advances silently, and by the time cough, breathlessness, chest pain, or weight loss appear, the disease may already be beyond the most curable stage.
Dr Stefano Santini, clinical director for the trust’s lung cancer screening programme, said the service exists because many people do not realise anything is wrong until cancer is more advanced. That clinical reality drives the entire design of the programme: identify people at highest risk, bring imaging to them, and intercept malignancy before it spreads.
Why Screening Is Reaching Into High-Risk Communities
The programme targets smokers and ex-smokers because tobacco exposure remains the dominant driver of lung cancer risk. Seven out of 10 lung cancer cases in the UK are caused by smoking, and the disease is the third most common cancer in the country. Around 26,000 people die from it every year.
Those numbers explain why screening has become more than a local service tweak. It is a cancer control strategy aimed at shifting diagnosis toward stages where surgery, radiotherapy, or other treatment options are more likely to succeed. For a disease that often remains hidden until late, the value of a low-threshold invitation is straightforward: bring the scan to the patient before the cancer brings the patient to hospital.
Dr Jonathan Bryant, clinical lead for NHS Kent and Medway Cancer Alliance, said attendance matters because the earlier the diagnosis, the more treatment options there are. In practical terms, that usually means more patients are found while the disease is still confined enough to treat aggressively and potentially with curative intent.
Stage Shift Has Become the Most Important Signal
The strongest sign of the programme’s impact is where cancers are being found. Since the targeted lung health check programme launched in November 2022 and was rebranded as the lung cancer screening programme, more than 120 lung cancers have been diagnosed in East Kent alone, with the vast majority at stages one or two.
Early-stage detection changes the trajectory of care. Small, localized tumors can often be approached very differently from advanced disease, when treatment is more likely to be palliative and survival prospects are markedly worse. NHS England says people diagnosed at the earliest stages are nearly 13 times more likely to survive five years than those whose cancer is caught late.
Ken Boorman’s experience from Dymchurch illustrates the human consequence behind that statistic. He received an invitation for a lung health check in May 2024 and was diagnosed with early-stage lung cancer in August 2025. He described the screening as lifesaving and urged others to attend.
One timely scan can change the whole treatment path.
The Service Is Spreading Across Kent and Medway
The Kent programme is being rolled out in phases across the county. It has already expanded across the south Kent coast, Canterbury, Whitstable, Faversham and Herne Bay. It is also in place in Dartford, with Medway and Swale due to follow by the beginning of 2028.
That stepped rollout reflects the scale of the disease burden as well as the logistics of delivering targeted screening across a wide population. The aim is not universal testing of everyone, but focused outreach to those at greatest risk, especially current and former smokers in the age bracket most likely to benefit from early detection.
For West Kent residents, the shift to Fordcombe as a screening site marks another stage in that regional expansion. The service model depends on accessibility. If attendance is poor, cancers stay hidden; if access is easy and the invitation lands in the right group, the programme can pick up disease before symptoms become irreversible evidence of progression.
What the Screening Programme Is Trying to Prevent
The biological logic is blunt. Lung tumours grow in a way that can remain clinically quiet for a long time, especially when they begin in peripheral areas of the lung or when respiratory symptoms are dismissed as smoking-related baseline complaints. By the time a person seeks care, the disease may already have invaded lymph nodes or metastasized.
Screening interrupts that sequence. Imaging can reveal nodules or suspicious lesions while they remain small enough to investigate and, if necessary, treat promptly. In a cancer where late presentation still drives much of the mortality, catching disease at stages one or two is not a marginal gain; it is the difference between a potentially curable diagnosis and a far more limited therapeutic outlook.
The programme also carries a wider preventive message. Smoking remains the main modifiable risk factor, and the existence of a screening pathway does not soften the underlying harm of tobacco exposure. Instead, it gives the NHS a way to identify damage sooner while reinforcing the need for cessation support and continued risk reduction.
Why Attendance Matters More Than Awareness Alone
Public awareness campaigns often fail when risk feels abstract. Lung cancer screening turns abstract risk into a booked appointment, a scan, and a result. For someone who feels well, the decision to attend can be easy to delay. Yet the clinical stakes are unusually high because the disease can progress without obvious warning.
The programme’s message is therefore direct: if you are in the eligible age group and have a history of smoking, attend. The benefit lies not in reassurance alone, but in finding disease early enough to preserve more treatment options and improve survival odds.
The Kent rollout now offers a real-world test of how far targeted screening can move diagnosis toward earlier stages across an at-risk population. The central unanswered issue is not whether lung cancer is serious; it is how many more cancers can be found before they are advanced, and whether expanded local access will keep pushing diagnoses into the window where treatment has the best chance of working.